資源描述：
《奧沙利鉑和吡喃阿霉素介入治療原發(fā)性肝癌療效和安全性》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、奧沙利鉗和毗喃阿霉素介入治療原發(fā)性肝癌療效和安全性【摘要】目的：對(duì)比分析原發(fā)性肝癌采用奧沙利苗和毗喃阿霉素介入治療的療效與安全性。方法：選取本院2009年1月-2012年12月收治的76例原發(fā)性肝癌患者作為研究對(duì)象，按照隨機(jī)數(shù)字表法將其分為為研究組與對(duì)照組各38例。研究組患者采取毗喃阿霉素介入治療，對(duì)照組則采取奧沙利鉗介入治療。觀察比較兩組患者治療效果與安全性，療效包括總有效率、疾病控制率、臨床癥狀改善率、腫瘤標(biāo)志物的下降率、疾病進(jìn)展時(shí)間、不良反應(yīng)發(fā)生率等；分析兩組中進(jìn)展時(shí)間大于12個(gè)月的患者情況，來(lái)判斷介入治療遠(yuǎn)期療效的影響因素。結(jié)果：研究組治療總有效率、平均疾病
2、無(wú)進(jìn)展時(shí)間和腫瘤標(biāo)志物下降率均明顯優(yōu)于對(duì)照組，比較差異有統(tǒng)計(jì)學(xué)意義（P0.05）。通過(guò)分析可知，介入治療遠(yuǎn)期療效的影響因素包括門(mén)靜脈受累、病灶有無(wú)包膜及術(shù)后合并應(yīng)用抗癌藥物等。結(jié)論：原發(fā)性肝癌患者采用毗喃阿霉素介入治療，有著安全與有效的優(yōu)勢(shì)，同時(shí)能提高疾病無(wú)進(jìn)展時(shí)間,相較于毗喃阿霉素介入治療效果更佳，值得臨床推廣及應(yīng)用。【關(guān)鍵詞】奧沙利卒白;毗喃阿霉素;介入治療；原發(fā)性肝癌；療效；安全性EfficacyandSafetyofOxaliplatinandPirarubicinInterventionintheTreatmentofPrimaryLiverCancer/
3、LIUXiao-hong,WANLin-lin,DINGWei,etal.//MedicalInnovationofChina,2013,10(35)：021-023[Abstract】Objective：ToanalyzeandcomparetheefficacyandsafetyofOxaliplatinandPirarubicininterventiononprimarylivercancer.Method:Seventy-sixprimarylivercancerpatientsinourhospitalfromJanuary2009toDecember20
4、12wereselectedastheresearchobjects,andthenrandomlydividedintothestudygroupandthecontrolgroup,38casesineachgroup.Thestudygroupwastreatedwithpirarubicinintervention,thecontrolgroupwastreatedwithinterventionaltherapy.Theeffectandsafetycomparisonoftwogroupswereanalyzed,includingtheincidenc
5、eofclinicaltotaleffectiverate,diseasecontrolrate,clinicalsymptomimprovementrateofdecline,therateoftumormarkers,timetoprogression,adversereaction；Timetoprogressionthanpatientsinthetwogroupsof12monthswereanalyzed,anddeterminedthefactorsthataffectonthelong-termeffectofinterventionaltherap
6、yResuIt:Thetotaleffectiverate,averageprogressionfreesurvivalandtumormarkerdeclinerateofthetreatmentgroupwerebetterthanthoseofthecontrolgroup,thedifferenceswerestatisticallysignificant(P0.05)?Throughtheanalysis,factorsaffectingthelong-termeffectofinterventionaltreatment,includingportalv
7、eininvolvement，lesionswerenonenvelopedandpostoperativecombinedwithanticancerdrugs.Conclusion：Inpatientswithprimarylivercancerwithpirarubicininterventiontherapy,isasafeandeffective,andcanimprovetheprogressionfreesurvival,comparedwithpirarubicininterventiontherapyeffectisbetter,itiswor
